Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

Bibliography

• The International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov 2010;7:215-36
   Google Scholar
• Storch C, Theile D, Lindenmaier H, Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007;73:1573-81
   PubMed Web of Science ®Google Scholar
• Zhou S. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310-22
   PubMed Web of Science ®Google Scholar
• Finch C, Chrisman C, Baciewicz A, Self T. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162:985-92
   PubMed Web of Science ®Google Scholar
• German P, Warren D, West S, Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55:323-9
   PubMed Web of Science ®Google Scholar
• Altice F, Kamarulzaman A, Soriano V, Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010;376:367-87
   PubMed Web of Science ®Google Scholar
• Uttayamakul S, Likanonsakul S, Manosuthi W, Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther 2010;7:8
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Morello J, Gonzalez M, Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated interferon and ribavirin. AIDS 2008;22:2535-7
   PubMed Web of Science ®Google Scholar
• Janssen Cilag. Intelence Prescribing Information; 2008
   Google Scholar
• Park-Wyllie LY, Levine M, Holbrook A, Outcomes of dosage adjustments used to manage antiretroviral drug interactions. Clin Infect Dis 2007;45:933-6
   PubMed Web of Science ®Google Scholar
• Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr 2003;34(Suppl 1):S8-14
   PubMed Web of Science ®Google Scholar
• Cvetkovic R, Goa K. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63:769-802
   PubMed Web of Science ®Google Scholar
• Le Tiec C, Barrail A, Goujard C, Taburet A. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005;44:1035-50
   PubMed Web of Science ®Google Scholar
• Poirier J, Guiard-Schmid J, Meynard J, Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors. AIDS 2006;20:1087-9
   PubMed Web of Science ®Google Scholar
• Katlama C, Clotet B, Mills A, Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010;15:1045-52
   PubMed Web of Science ®Google Scholar
• Hicks C, Gulick R. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009;48:931-9
   PubMed Web of Science ®Google Scholar
• Wenning L, Hanley W, Brainard D, Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009;53:2852-6, Iwamoto
   PubMed Web of Science ®Google Scholar
• Abel S, Back D, Vourvahis M. Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 2009;14:607-18
   PubMed Web of Science ®Google Scholar
• Jenny-Avital E, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 2009;48:1471-4
   PubMed Web of Science ®Google Scholar
• Khachi H, O'Connell R, Ladenheim D, Orkin C. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 2009;64:871-3
   PubMed Web of Science ®Google Scholar
• Kwara A, Ramachandran G, Swaminathan S. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin Drug Metab Toxicol 2010;6:55-68
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Padmapriyadarsini C, Narendran G. HIV-associated tuberculosis: clinical update. Clin Infect Dis 2010;50:1377-86
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Sungkanuparph S, Tantanathip P, A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009;48:1752-9
   PubMed Web of Science ®Google Scholar
• Sekar V, Spinosa-Guzman S, De Paepe E, Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. J Clin Pharmacol 2008;48:60-5
   PubMed Web of Science ®Google Scholar
• Yakiwchuk E, Foisy M, Hughes C. Complexity of interactions between voriconazole and antiretroviral agents. Ann Pharmacother 2008;42:698-703
   PubMed Web of Science ®Google Scholar
• Scholler-Gyure M, Kakuda N, Van Solingen-Ristea R, Aharchi F. Pharmacokinetic interaction between etravirine and fluconazole or voriconazole in HIV-negative volunteers [abstract A1-1299]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009
   Google Scholar
• Kempf D, Klein C, Chen H, Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007;18:163-7
   PubMedGoogle Scholar
• Hezode C, Forestier N, Dusheiko G, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50
   PubMed Web of Science ®Google Scholar
• Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010;65:1079-85
   PubMed Web of Science ®Google Scholar
• Vispo E, Barreiro P, Pineda JA, Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008;13:429-37
   PubMed Web of Science ®Google Scholar
• Crabbe R, Vuagniaux G, Dumont JM, An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin Investig Drugs 2009;18:211-20
   PubMed Web of Science ®Google Scholar
• Khachi H, O'Connell R, Ladenheim D, Orkin C. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 2009;64:871-3
   PubMed Web of Science ®Google Scholar
• Izzedine H, Launay-Vacher V, Baumelou A, Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 2004;66:532-41
   PubMed Web of Science ®Google Scholar
• Johnson R, Chutuape M, Strain E, A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343:1290-7
   PubMed Web of Science ®Google Scholar
• Moody D, Alburges M, Parker R, The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997;25:1347-53
   PubMed Web of Science ®Google Scholar
• Chang Y, Fang W, Lin S, Moody D. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol 2011;108:55-62
   PubMed Web of Science ®Google Scholar
• Ferrari A, Coccia C, Bertolini A, Sternieri E. Methadone -metabolism, pharmacokinetics and interactions. Pharmacol Res 2004;50:551-9
   PubMed Web of Science ®Google Scholar
• Bruce R, Altice F, Gourevitch M, Friedland G. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006;41:563-72
   PubMed Web of Science ®Google Scholar
• Lugo R, Satterfield K, Kern S. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005;19:13-24
   PubMedGoogle Scholar
• Maas B, Kerr T, Fairbairn N, Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence. Expert Opin Drug Metab Toxicol 2006;2:533-43
   PubMed Web of Science ®Google Scholar
• Otero MJ, Fuertes A, Sanchez R, Luna G. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS 1999;13:1004-5
   PubMed Web of Science ®Google Scholar
• Clarke S, Mulcahy F, Tjia J, The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001;51:213-17
   PubMed Web of Science ®Google Scholar
• Kharasch E, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76:250-69
   PubMed Web of Science ®Google Scholar
• Bart P, Rizzardi P, Gallant S, Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit 2001;23:553-5
   PubMed Web of Science ®Google Scholar
• Pardo MA, Cuadrado JM, Perez MP, Fernandez V. Opiates withdrawal syndrome after treatment with zidovudine + lamivudine + abacavir in patients with positivity for HIV and treated with methadone. Rev Clin Esp 2003;203:407-8
   PubMed Web of Science ®Google Scholar
• Bruce R, McCance-Katz E, Kharasch E, Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis 2006;43(Suppl 4):S216-23
   PubMedGoogle Scholar
• McCance-Katz E, Moody D, Smith P, Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. Clin Infect Dis 2006;43(Suppl 4):S235-46
   PubMedGoogle Scholar
• McCance-Katz E, Moody D, Morse G, Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors Efavirenz and Delavirdine. Clin Infect Dis 2006;43(Suppl 4):S224-34
   PubMedGoogle Scholar
• Antoniou T, Tseng A. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002;36:1598-613
   PubMed Web of Science ®Google Scholar
• Henry J, Hill I. Fatal interaction between ritonavir and MDMA. Lancet 1998;352:1751-2
   PubMed Web of Science ®Google Scholar
• Harrington R, Woodward J, Hooton T, Horn J. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999;159:2221-4
   PubMed Web of Science ®Google Scholar
• Liedtke M, Lockhart S, Rathbun R. Anticonvulsant and antiretroviral interactions. Ann Pharmacother 2004;38:482-9
   PubMed Web of Science ®Google Scholar
• van der Lee M, Dawood L, ter Hofstede H, Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 2006;80:159-68
   PubMed Web of Science ®Google Scholar
• Gallo C, de la Fuente B, Garcia-Alcalde ML, Antuna A. Ergotism in a patient treated with ritonavir and ergotamine. Med Clin (Barc) 2002;119:558-9
   PubMed Web of Science ®Google Scholar
• Falcon R, Kakuda T. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet 2008;47:75-89
   PubMed Web of Science ®Google Scholar
• Kiser J, Bumpass J, Meditz A, Effect of antacids on the pharmacokinetics of raltegravir in HIV-seronegative volunteers. Antimicrob Agents Chemother 2010;54:4999-5003
   PubMed Web of Science ®Google Scholar
• Croom K, Dhillon S, Keam S. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 2009;69:1107-40
   PubMed Web of Science ®Google Scholar
• Hall M, Ahmad S. Interaction between sildenafil and HIV-1 combination therapy. Lancet 1999;353:2071-2
   PubMed Web of Science ®Google Scholar
• Muirhead G, Wulff M, Fielding A, Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000;50:99-107
   PubMed Web of Science ®Google Scholar
• Hulgan T, Sterling T, Daugherty J, Prescribing of contraindicated protease inhibitors and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr 2005;38:277-82
   PubMed Web of Science ®Google Scholar
• Ray G. Antiretroviral and statin drug-drug interactions. Cardiol Rev 2009;17:44-7
   PubMed Web of Science ®Google Scholar
• Busti A, Bain A, Hall R, Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 2008;51:605-10
   PubMed Web of Science ®Google Scholar
• Llibre JM, Romeu J, Lopez E, Sirera G. Severe interaction between ritonavir and acenocoumarol. Ann Pharmacother 2002;36:621-3
   PubMed Web of Science ®Google Scholar
• Knoell K, Young T, Cousins E. Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998;32:1299-302
   PubMed Web of Science ®Google Scholar
• Liedtke M, Rathbun R. Warfarin-antiretroviral interactions. Ann Pharmacother 2009;43:322-8
   PubMed Web of Science ®Google Scholar
• Park-Wyllie L, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 2003;17:638-40
   PubMed Web of Science ®Google Scholar
• Hogeland G, Swindells S, McNabb J, Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 2007;81:69-75
   PubMed Web of Science ®Google Scholar
• Pfizer Ltd. Champix Summary of Product Characteristics; 2008
   Google Scholar
• Ouellet D, Hsu A, Qian J, Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46:111-16
   PubMed Web of Science ®Google Scholar
• El Ibiary S, Cocohoba J. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008;13:123-32
   PubMed Web of Science ®Google Scholar
• Touzot M, Beller C, Touzot F, Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient. AIDS 2006;20:1210-12
   PubMed Web of Science ®Google Scholar
• Samaras K, Pett S, Gowers A, Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005;90:4394-8
   PubMed Web of Science ®Google Scholar
• Rivera J, Gonzalez-Stuart A, Ortiz M, Herbal product use in non-HIV and HIV-positive Hispanic patients. J Natl Med Assoc 2005;97:1686-91
   PubMedGoogle Scholar
• Pal D, Mitra A. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006;78:2131-45
   PubMed Web of Science ®Google Scholar
• van den Bout-van den Beukel C, Koopmans P, van der Ven A, Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev 2006;38:477-514
   PubMed Web of Science ®Google Scholar
• Mauss S, Valenti W, DePamphilis J, Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21-5
   PubMed Web of Science ®Google Scholar
• Barreiro P, Soriano V. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother 2006;57:806-9
   PubMed Web of Science ®Google Scholar
• Brown K, Paul S, Kashuba A. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 2009;48:211-41
   PubMed Web of Science ®Google Scholar